Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19

Thomas D. Norton; Mazhar Thakur; Samit Ganguly; Shazia Ali; Jesse Chao; Alpana Waldron; Jing Xiao; Kenneth C. Turner; John D. Davis; Susan C. Irvin; Cynthia Pan; Dominique Atmodjo; Andrea T. Hooper; Jennifer D. Hamilton; Mohamed Hussein; Danise Subramaniam; Lilia Roque-Guerrero; Anita Kohli; Eleftherios Mylonakis; Gregory P. Geba; Edward Cox; Ned Braunstein; Paula Dakin; Bari Kowal; Rafia Bhore; A. Thomas DiCioccio; Diana Hughes; Gary A. Herman

doi:10.1093/jpids/piae105

Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19

Thomas D. Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse Chao, Alpana Waldron, Jing Xiao, Kenneth C. Turner, John D. Davis, Susan C. Irvin, Cynthia Pan, Dominique Atmodjo, Andrea T. Hooper, Jennifer D. Hamilton, Mohamed Hussein, Danise Subramaniam, Lilia Roque-Guerrero, Anita Kohli, Eleftherios Mylonakis, Gregory P. GebaEdward Cox, Ned Braunstein, Paula Dakin, Bari Kowal, Rafia Bhore, A. Thomas DiCioccio, Diana Hughes, Gary A. Herman

Research output: Contribution to journal › Article › peer-review

Abstract

The safety of casirivimab + imdevimab (CAS + IMD) (anti-severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] monoclonal antibodies [mAbs]) in pediatric outpatients with coronavirus disease 2019 (COVID-19) was evaluated in a randomized phase 1/2/3 trial. Consistent with adults, CAS + IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support the development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.

Original language	English (US)
Pages (from-to)	589-593
Number of pages	5
Journal	Journal of the Pediatric Infectious Diseases Society
Volume	13
Issue number	11
DOIs	https://doi.org/10.1093/jpids/piae105
State	Published - Nov 1 2024

Keywords

COVID-19
monoclonal antibodies
outpatients
pediatrics
treatment

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Infectious Diseases

Divisions

Infectious Disease

Access to Document

10.1093/jpids/piae105

Cite this

Norton, T. D., Thakur, M., Ganguly, S., Ali, S., Chao, J., Waldron, A., Xiao, J., Turner, K. C., Davis, J. D., Irvin, S. C., Pan, C., Atmodjo, D., Hooper, A. T., Hamilton, J. D., Hussein, M., Subramaniam, D., Roque-Guerrero, L., Kohli, A., Mylonakis, E., ... Herman, G. A. (2024). Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19. Journal of the Pediatric Infectious Diseases Society, 13(11), 589-593. https://doi.org/10.1093/jpids/piae105

Norton, TD, Thakur, M, Ganguly, S, Ali, S, Chao, J, Waldron, A, Xiao, J, Turner, KC, Davis, JD, Irvin, SC, Pan, C, Atmodjo, D, Hooper, AT, Hamilton, JD, Hussein, M, Subramaniam, D, Roque-Guerrero, L, Kohli, A, Mylonakis, E, Geba, GP, Cox, E, Braunstein, N, Dakin, P, Kowal, B, Bhore, R, DiCioccio, AT, Hughes, D & Herman, GA 2024, 'Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19', Journal of the Pediatric Infectious Diseases Society, vol. 13, no. 11, pp. 589-593. https://doi.org/10.1093/jpids/piae105

@article{94f51df7409e40fa9b38be56355c5284,

title = "Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19",

abstract = "The safety of casirivimab + imdevimab (CAS + IMD) (anti-severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] monoclonal antibodies [mAbs]) in pediatric outpatients with coronavirus disease 2019 (COVID-19) was evaluated in a randomized phase 1/2/3 trial. Consistent with adults, CAS + IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support the development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.",

keywords = "COVID-19, monoclonal antibodies, outpatients, pediatrics, treatment",

author = "Norton, \{Thomas D.\} and Mazhar Thakur and Samit Ganguly and Shazia Ali and Jesse Chao and Alpana Waldron and Jing Xiao and Turner, \{Kenneth C.\} and Davis, \{John D.\} and Irvin, \{Susan C.\} and Cynthia Pan and Dominique Atmodjo and Hooper, \{Andrea T.\} and Hamilton, \{Jennifer D.\} and Mohamed Hussein and Danise Subramaniam and Lilia Roque-Guerrero and Anita Kohli and Eleftherios Mylonakis and Geba, \{Gregory P.\} and Edward Cox and Ned Braunstein and Paula Dakin and Bari Kowal and Rafia Bhore and DiCioccio, \{A. Thomas\} and Diana Hughes and Herman, \{Gary A.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = nov,

day = "1",

doi = "10.1093/jpids/piae105",

language = "English (US)",

volume = "13",

pages = "589--593",

journal = "Journal of the Pediatric Infectious Diseases Society",

issn = "2048-7193",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19

AU - Norton, Thomas D.

AU - Thakur, Mazhar

AU - Ganguly, Samit

AU - Ali, Shazia

AU - Chao, Jesse

AU - Waldron, Alpana

AU - Xiao, Jing

AU - Turner, Kenneth C.

AU - Davis, John D.

AU - Irvin, Susan C.

AU - Pan, Cynthia

AU - Atmodjo, Dominique

AU - Hooper, Andrea T.

AU - Hamilton, Jennifer D.

AU - Hussein, Mohamed

AU - Subramaniam, Danise

AU - Roque-Guerrero, Lilia

AU - Kohli, Anita

AU - Mylonakis, Eleftherios

AU - Geba, Gregory P.

AU - Cox, Edward

AU - Braunstein, Ned

AU - Dakin, Paula

AU - Kowal, Bari

AU - Bhore, Rafia

AU - DiCioccio, A. Thomas

AU - Hughes, Diana

AU - Herman, Gary A.

PY - 2024/11/1

Y1 - 2024/11/1

N2 - The safety of casirivimab + imdevimab (CAS + IMD) (anti-severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] monoclonal antibodies [mAbs]) in pediatric outpatients with coronavirus disease 2019 (COVID-19) was evaluated in a randomized phase 1/2/3 trial. Consistent with adults, CAS + IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support the development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.

AB - The safety of casirivimab + imdevimab (CAS + IMD) (anti-severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] monoclonal antibodies [mAbs]) in pediatric outpatients with coronavirus disease 2019 (COVID-19) was evaluated in a randomized phase 1/2/3 trial. Consistent with adults, CAS + IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support the development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.

KW - COVID-19

KW - monoclonal antibodies

KW - outpatients

KW - pediatrics

KW - treatment

UR - https://www.scopus.com/pages/publications/85211393206

UR - https://www.scopus.com/inward/citedby.url?scp=85211393206&partnerID=8YFLogxK

U2 - 10.1093/jpids/piae105

DO - 10.1093/jpids/piae105

M3 - Article

C2 - 39351798

AN - SCOPUS:85211393206

SN - 2048-7193

VL - 13

SP - 589

EP - 593

JO - Journal of the Pediatric Infectious Diseases Society

JF - Journal of the Pediatric Infectious Diseases Society

IS - 11

ER -

Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19

Abstract

Keywords

ASJC Scopus subject areas

Divisions

Access to Document

Other files and links

Fingerprint

Cite this